


PROGRAMME OVERVIEW



SCIENTIFIC PROGRAMME

Thursday 19 April 2018

	09.00–09.15	Official Opening
		Co-Chairs: <i>Mauro Schechter, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil</i> <i>Juan Sierra-Madero, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico</i>
O11	09.15–10.45	Role of Integrase Inhibitors in LATAM: Are We Ready for First Line? Session Supported by an Independent Educational Grant from ViiV Healthcare
O11CH		Co-Chairs: <i>Mauro Schechter</i>
O11CH		<i>Juan Sierra-Madero</i>
O111	09.15–09.35	Current role of integrase inhibitors in Latin American guidelines <i>Ernesto Martínez-Buitrago, Infectious Diseases, Santiago de Cali, Colombia</i>
O112	09.35–09.55	Observational studies with integrase inhibitors and experience with first-line use in Brazil <i>Ricardo Sobhie Diaz, Federal University of São Paulo, São Paulo, Brazil</i>
O113	09.55–10.15	The public health response to rising pretreatment HIV drug resistance levels in Latin America: the case of Mexico <i>Santiago Ávila Ríos, Centre for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico</i>
	10.15–10.45	Discussion
	10.45–11.00	Coffee
KL11	11.00–12.00	Keynote Lectures
KL11CH		Co-Chairs: <i>Anton Pozniak, Chelsea and Westminster Hospital, London, UK</i>
KL11CH		<i>Mónica Thormann, Salvador B Gautier Hospital, Santo Domingo, Dominican Republic</i>
KL111	11.00–11.30	What is needed to end HIV/AIDS? <i>Demetre Daskalakis, New York City Department of Health and Mental Hygiene, New York, NY, USA</i>
KL112	11.30–12.00	What do we mean in our region by ending AIDS? <i>Jean W Pape, Les Centres, GHESKIO, Port-au-Prince, Haiti, and Center for Global Health, Division of Infectious Diseases, Weill Cornell Medicine, Cornell University, New York, NY, USA</i>
O12	12.00–13.30	TB Diagnosis and Treatment: An Update for the Region
O12CH		Co-Chairs: <i>Massimo N Ghidinelli, Pan American Health Organization, Washington, DC, USA</i>
O12CH		<i>Marcelo Losso, Hospital General de Agudos JM Ramos Mejía, Buenos Aires, Argentina</i>
O121	12.00–12.20	New methods for TB diagnosis <i>Rafael López, Tuberculosis Prevention, Control and Elimination, Pan American Health Organization (PAHO), Washington, DC, USA</i>
O122	12.20–12.40	Treatment for drug-resistant TB <i>Anton Pozniak</i>

SCIENTIFIC PROGRAMME (continued)

O123	12.40–12.55	First-hand experience from Brazil: lessons learned <i>Ezio Távora dos Santos-Filho, Grupo Pela Vida-RJ, Rio de Janeiro, Brazil</i>
O124*	12.55–13.10	Safety and efficacy of dolutegravir-based ART in TB/HIV co-infected adults at Week 24 <i>Eduardo Ticona, Tropical and Infectious Diseases, Hospital Dos de Mayo, Lima, Peru</i>
	13.10–13.30	Discussion
	13.30–14.45	Scientific Posters and Lunch
KL12	14.45–15.45	Keynote Lectures
KL12CH KL12CH		Co-Chairs: <i>Pedro Cahn, Fundación Huésped, Buenos Aires, Argentina</i> <i>Patricia Volkow, National Institute of Cancer, Mexico City, Mexico</i>
KL121	14.45–15.15	The microbiome in HIV infection <i>Sandra Pinto-Cardoso, Center for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico</i>
KL122	15.15–15.45	Early treatment of HIV in infants <i>Karin A Nielsen, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA</i>
O13	15.45–16.40	Women with HIV in Latin America
O13CH O13CH		Co-Chairs: <i>Pedro Cahn</i> <i>Patricia Volkow</i>
O131	15.45–16.05	Diagnosis and treatment of HIV-positive women with comorbidities <i>Mónica Mantilla Suárez, CEPAIN IPS, and Virrey Solís IPS, Bogotá, Colombia</i>
O132	16.05–16.25	ARV safety in pregnancy <i>Vanessa Rouzier, Integrated Care Center and Research Institution, Les Centres, GHESKIO, Port-au-Prince, Haiti</i>
O133*	16.25–16.40	HIV-infected pregnant adolescents are an extremely vulnerable population: a cohort study of PMTCT outcomes in Haiti <i>Marie M Deschamps, GHESKIO, Port-au-Prince, Haiti</i>
	16.40–17.00	Coffee
SS1	17.00–18.30	Challenging the Status Quo of HIV in the Americas Gilead Sciences Satellite Symposium
SS1CH		Chair: <i>Luis Soto-Ramírez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico</i>
SS1CH	17.00–17.05	Introduction <i>Luis Soto-Ramírez</i>
SS11	17.05–17.30	Current situation of regional efforts at screening, diagnosing and linking to care <i>Ernesto Martínez-Buitrago</i>
SS12	17.30–17.55	The current and future status of regional ART guidelines <i>Alejandro Afani, Immunology Section, Department of Medicine, Clinical Hospital, University of Chile, Santiago de Chile, Chile</i>

*Abstract accepted for oral presentation. See page 12 for full author listing.

SCIENTIFIC PROGRAMME (continued)

SS13	17.55–18.20	The value of INSTI- and TAF-containing STRs in both naïve and switch patients <i>Luis Soto-Ramirez</i>
	18.20–18.30	Discussion All faculty, led by <i>Luis Soto-Ramirez</i>
	18.30–19.15	Welcome Reception and Posters

Friday 20 April 2018

SS2	09.00–10.30	Integrated HIV Management: Know Your Patients and Their Needs Merck Sharp & Dohme Satellite Symposium
SS2CH		Chair: <i>Mauro Schechter</i>
SS2CH	09.00–09.10	Opening and welcome <i>Mauro Schechter</i>
SS2CH	09.10–09.30	Comorbidities and the need for total patient care <i>Mauro Schechter</i>
SS21	09.30–09.50	How resistance patterns influence individual treatment choices <i>José Luis Blanco, Hospital Clinic Universitari Barcelona, Barcelona, Spain</i>
SS22	09.50–10.10	The importance of tailoring HIV regimens to the individual patient <i>Pedro Cahn</i>
SS23	10.10–10.25	Clinical cases/faculty round table discussion All faculty, led by <i>Mauro Schechter</i>
SS2CH	10.25–10.30	Closing remarks <i>Mauro Schechter</i>
	10.30–10.45	Coffee
KL21	10.45–11.15	Keynote Lecture
KL21CH		Co-Chairs: <i>Ernesto Martínez-Buitrago</i>
KL21CH		<i>Ian Weller, University College London Medical School, London, UK</i>
KL211	10.45–11.15	Update on PEP and on its role in the era of PrEP <i>Dawn K Smith, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA</i>
O21	11.15–11.55	HIV and Vulnerable Populations
O21CH		Co-Chairs: <i>Ernesto Martínez-Buitrago</i>
O21CH		<i>Ian Weller</i>
O211	11.15–11.35	Transgender people <i>Benjamim Braga, Cuiabá, Brazil</i>
O212	11.35–11.55	Adolescents <i>Daisy Machado, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil</i>
	11.55–13.00	Scientific Posters and Lunch

SCIENTIFIC PROGRAMME (continued)

O22	13.00–14.45	Hepatitis C. New Drugs and What Can We Learn from HIV?
O22CH		Co-Chairs: <i>Mario Pessoa, University of São Paulo, São Paulo, Brazil</i>
O22CH		<i>Alicia Piñeirúa-Menendez, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico</i>
O221	13.00–13.20	New HCV drugs in the region <i>Mark Nelson, Chelsea and Westminster Hospital, London, UK</i>
O222	13.20–13.40	Home/self-testing: when, to whom? Experience from HIV <i>Omar Sued, Fundación Huésped, Buenos Aires, Argentina</i>
O223	13.40–14.00	Translating lessons from HIV to hepatitis C <i>Jorge L. Santana, University of Puerto Rico School of Medicine, San Juan, Puerto Rico</i>
O224*	14.00–14.15	Risk factors for transmission of hepatitis C virus among the HIV population in Central Mexico: a case-control study <i>Luis Esteban Ramírez-Gonzalez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico</i>
	14.15–14.45	Discussion
	14.45–15.15	Coffee
O23	15.15–15.30	Submitted Abstract
O23CH		Chair: <i>Roy M Gulick, Weill Cornell Medicine, New York, NY, USA</i>
O231*	15.15–15.30	Switch to bictegrovir/F/TAT from DTG and ABC/3TC <i>Monica Mora, Gilead Sciences Inc, Foster City, CA, USA</i>
O24	15.30–17.00	State-of-the-ART
O24CH		Co-Chairs: <i>Carlos J Beltrán, Hospital Barros Luco Trudeau, and University of Santiago, Santiago, Chile</i>
O24CH		<i>Roy M Gulick</i>
O241	15.30–15.50	Dual therapy <i>Pedro Cahn</i>
O242	15.50–16.20	HIV and new drugs <i>Daniel R Kuritzkes, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA</i>
O243	16.20–17.00	Round table discussion All faculty, led by <i>Roy M Gulick</i> , and joined by <i>Mauro Schechter</i> and <i>Juan Sierra-Madero</i>

*Abstract accepted for oral presentation. See page 12 for full author listing.

SCIENTIFIC PROGRAMME (continued)

O25	17.00–17.45	Submitted Abstract and CROI Review
O25CH		Chair: <i>Ricardo Sobhie Díaz</i>
O251*	17.00–17.15	Transmitted drug resistance trends in individuals with recent infection in the Mesoamerican Region <i>Daniela Tapia-Trejo, Center for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico</i>
O252	17.15–17.45	Key Data from CROI 2018 <i>Luis Soto-Ramírez</i>
	17.45–18.00	Coffee
SS3	18.00–19.00	Towards a Hepatitis C Elimination Program: A New Simple Pangenotypic Regimen Gilead Sciences Satellite Symposium
SS3CH		Chair: <i>Juan Sierra-Madero</i>
SS3CH	18.00–18.05	Introduction <i>Juan Sierra-Madero</i>
SS31	18.05–18.25	HCV elimination program: strategies in Latin America <i>Mario Pessoa</i>
SS32	18.25–18.45	Pangenotypic regimen: a step forward in HCV treatment <i>Adrian Gadano, University of Buenos Aires, Buenos Aires, Argentina</i>
	18.45–19.00	Discussion Led by <i>Juan Sierra-Madero</i>
	19.00–19.45	Reception and Posters

Saturday 21 April 2018

CS1	09.00–10.30	Challenging Cases in HIV Interactive Case Study Session in Collaboration with the International Antiviral Society-USA (IAS-USA)
CS1CH		Moderator: <i>Roy M Gulick</i>
CS11	09.00–09.30	What to start? <i>Brenda Crabtree-Ramírez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico</i>
CS12	09.30–10.00	Treatment failure <i>Carlos J Beltrán</i>

*Abstract accepted for oral presentation. See page 12 for full author listing.

SCIENTIFIC PROGRAMME (continued)

CS13	10.00–10.30	PrEP <i>Kenneth Mayer, Fenway Community Health Center, Boston, MA, USA</i>
		Panellists: <i>Carlos J Beltrán</i> <i>Brenda Crabtree-Ramírez</i> <i>Roy M Gulick</i> <i>Kenneth Mayer</i>
	10.30–10.45	Coffee
O31	10.45–12.15	Perspectives in Public Health: Old STIs – New Challenges <i>In Collaboration with the Pan American Health Organization (PAHO)</i>
O31CH		Chair: <i>Massimo N Ghidinelli</i>
O31CH		Facilitator: <i>Maeve B Mello, Pan American Health Organization, Washington, DC, USA</i>
O311	10.45–11.05	Historic perspectives and public health significance of syphilis and other sexually transmitted infections <i>Massimo N Ghidinelli and Maeve B Mello</i>
O312	11.05–11.20	Syphilis among key populations <i>Mary Kamb, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA</i>
O313	11.20–11.35	Innovation: community-based STI clinic and interventions in San Francisco <i>Jeffrey Klausner, Ronald Reagan UCLA Medical Center, and Zuckerberg San Francisco General Hospital and Trauma Center, Los Angeles, CA, USA</i>
O314	11.35–11.50	Outcomes of HIV and syphilis infection among pregnant women in Haiti <i>Marie M Deschamps</i>
	11.50–12.15	Discussion
	12.15–12.30	Coffee
O32	12.30–14.15	Update on Pre-Exposure Prophylaxis (PrEP) <i>In Collaboration with the International AIDS Society (IAS)</i>
O32CH		Co-Chairs: <i>Brenda Crabtree-Ramírez</i>
O32CH		<i>Mauro Schechter</i>
O321	12.30–12.50	PrEP: from clinical trials to implementation <i>Kenneth Mayer</i>
O322	12.50–13.10	HIV prevention: PrEP situation in Latin American countries <i>Giovanni Ravasi, Pan American Health Organization (PAHO), Washington, DC, USA</i>
O323	13.10–13.30	PrEP of HIV in Mexico: adding colour to the prevention palette <i>Hugo López-Gatell, National Institute of Public Health, Mexico City, Mexico</i>
	13.30–14.15	Discussion/debate
	14.15–14.30	Conference Close
	14.30–15.15	Lunch

SCIENTIFIC PROGRAMME (continued)

Submitted abstracts accepted for oral presentation within the Scientific Programme, illustrating full author group and affiliations.

- O124 **Safety and efficacy of dolutegravir-based ART in TB/HIV co-infected adults at Week 24**
K Dooley¹; R Kaplan²; TN Mwelase³; B Grinsztejn⁴; E Ticona^{4,5}; M Lacerda⁶; P Cahn⁷; E Belonosova⁸; M Ait-Khaled⁹; K Angelis¹⁰; D Brown¹¹; R Singh¹²; C Talarico¹³; M Aboud¹⁴
¹Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ²Infectious Disease, Desmond Tutu HIV Foundation, Cape Town, South Africa; ³Clinical HIV Research Unit, Johannesburg, South Africa; ⁴Infectious Disease, Instituto de Pesquisa Clínica Evandro Chagas Fiocruz, Rio de Janeiro, Brazil; ⁵Tropical and Infectious Diseases, Hospital Dos de Mayo, Lima, Peru; ⁶Fiocruz/Tropical Medicine Foundation Dr Heitor, Manaus, Brazil; ⁷Fundación Huesped, Buenos Aires, Argentina; ⁸Regional Center for Prevention and Treatment of AIDS and Infectious Diseases, Moscow, Russian Federation; ⁹Clinical Development, ViiV Healthcare, Brentford, UK; ¹⁰Statistics, GlaxoSmithKline, Stockley Park, UK; ¹¹Clinical Pharmacology, ViiV Healthcare, Abbotsford, Australia; ¹²Global Medical Dolutegravir, GlaxoSmithKline, Upper Merion, PA, USA; ¹³Clinical Development, ViiV Healthcare, Research Triangle Park, NC, USA; ¹⁴Global Medical Dolutegravir, ViiV Healthcare, Research Triangle Park, NC, USA
- O133 **HIV-infected pregnant adolescents are an extremely vulnerable population: a cohort study of PMTCT outcomes in Haiti**
*MM Deschamps^{*1}; V Rouzier²; D Jannat-Khah³; J Bonhomme⁴; J Pierrot⁵; L Reif⁶; JW Pape¹; M McNairy⁶*
¹GHESKIO, Port-au-Prince, Haiti; ²Paediatrics, GHESKIO, Port-au-Prince, Haiti; ³General Internal Medicine, Weill Cornell Medicine, New York, NY, USA; ⁴Obstetrics, GHESKIO, Port-au-Prince, Haiti; ⁵Data Management, GHESKIO, Port-au-Prince, Haiti; ⁶Center for Global Health, Weill Cornell Medicine, New York, NY, USA
- O224 **Risk factors for transmission of hepatitis C virus among the HIV population in Central Mexico: a case-control study**
*LE Ramírez-Gonzalez^{*1}; A Piñeirúa-Menendez²; JF Sanchez-Avila³; AH Hirata-Hernandez⁴; A Camiro-Zuñiga¹; E Simental-Aldaba¹; I Zamora-Tapia¹; J Sierra-Madero¹*
¹Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico; ²HIV, Clínica Codnesa Iztapalapa, Mexico City, Mexico; ³Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico; ⁴Mental Health, Clínica Condesa Iztapalapa, Mexico City, Mexico
- O231 **Switch to bictegravir/F/TA from DTG and ABC/3TC**
*J-M Molina¹; D Ward²; HJ Stellbrink³; D Podzamczar⁴; C Brinson⁵; K Andreatta⁶; H Martin⁶; A Cheng⁶; M Mora^{*6}; E Quirk⁶*
¹Hopital Saint Louis, Paris, France; ²DuPont Circle Physicians, Washington, DC, USA; ³ICH Study Center, Hamburg, Germany; ⁴Hospital Universitari de Bellvitge, Barcelona, Spain; ⁵Central Texas Clinical Research, Austin, TX, USA; ⁶Gilead Sciences Inc, Foster City, CA, USA
- O251 **Transmitted drug resistance trends in individuals with recent infection in the Mesoamerican Region**
*D Tapia-Trejo^{*1}; S Ávila Ríos¹; C García Morales¹; R Pinzón Meza²; J Miguel Pascale³; G Porras Cortes⁴; C Quant Durán⁵; I Lorenzana⁶; RI Meza Martínez⁷; E Yolanda Palou⁸; G Reyes Terán¹*
¹Center for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico; ²Infectious Disease Clinic, Hospital Roosevelt, Guatemala City, Guatemala; ³Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá, Panamá; ⁴Hospital Vivian Pellas, Managua, Nicaragua; ⁵Hospital Roberto Calderón, Managua, Nicaragua; ⁶Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras; ⁷Laboratorio Nacional de VIH, Tegucigalpa, Honduras; ⁸Instituto Nacional Cardio-Pulmonar, Tegucigalpa, Honduras

*Indicates presenting author.

POSTER PRESENTATIONS

All Scientific Posters have been arranged into the following categories and numbers:

Category	Poster number
Comorbidities and Complications of Disease and/or Treatment	P001–P010
HIV/Hepatitis Co-infection	P011–P017
HIV and Tuberculosis	P019–P021
HIV and Women, Including MTCT	P022–P023
HIV and Vulnerable Populations	P024–P033
Models of Care/Scale-Up of Treatment	P035–P043
Non-AIDS Morbidities and Mortality, and Ageing	P044–P046
Treatment Strategies and Outcomes	P047–P054
Viral Hepatitis	P055–P064
Virology and Immunology	P065–P066

Comorbidities and Complications of Disease and/or Treatment

P001	Dynamics of CD4 lymphocytes in patients infected by HIV with non-Hodgkin lymphoma <i>Alatorre Fernández, P*;</i> Volkow, P (Mexico City, Mexico)
P002	Renal function in perinatally HIV-1-infected patients <i>Al Hammoud, R*;</i> Perez, N; Rodriguez, G; Benjamins, L; Del Bianco, G; Murphy, J; Heresi, G (Houston, TX, USA)
P003	Frequency and distribution of cardiometabolic comorbidities in clinically stable HIV patients on long-term ARV therapy in Lima-Callao, Peru <i>Hidalgo, J*;</i> Florez, A; Agurto, C; Pinedo, Y; Ayarza, R; Rodriguez, L; La Rosa, A; Gutierrez, R (Lima, Peru)
P004	Renal insufficiency in HIV/AIDS patients: 5-year experience in an intensive care unit <i>Chediack, V;</i> Ricart, J*; <i> Sanchez Cunto, M; Dominguez, C; Mammoliti, G; Yesica, L; Nano, M; Gonzalez, L; Fernandez, J; Cunto, E; Nogueras, C (Buenos Aires, Argentina)</i>
P005	AIDS-related <i>pneumocystis jiroveci</i> pneumonia in an intensive care unit: a descriptive study <i>Ricart, J*;</i> Sanchez Cunto, M; Chediack, V; Dominguez, C; Gregori Sabelli, R; Cortez, E; Fernandez, J; Velasquez Lopez, P; Caceres, S; Cunto, E (Buenos Aires, Argentina)
P006	Latin American prospective cohort of adult HIV-positive patients (LATINA): factors associated with presenting symptoms at diagnosis <i>Rodriguez Loria, G*;</i> Mosqueda, L; Andrade Villanueva, J; Losso, M; Viloria, G; Hercilla, L; Mantilla Suárez, M; Lopardo, G; Michaan, M; Sanchez, M; Belloso, W (Buenos Aires, Argentina)
P007	Latin American prospective cohort of adult HIV-positive patients (LATINA): 2017 baseline characteristics update <i>Rodriguez Loria, G*;</i> Mosqueda, L; Andrade Villanueva, J; Losso, M; Viloria, G; Hercilla, L; Mantilla Suárez, M; Lopardo, G; Michaan, M; Sanchez, M; Belloso, W (Buenos Aires, Argentina)
P008	Comorbidities in a sample of HIV-positive adults in Colombia. Sub-analysis of patients younger than 50 years <i>Martínez, P;</i> Ruiz, J; Beltran, C; Rojas, M; Leon, S*; <i> Lenis, W (Bogotá, Colombia)</i>
P009	Problems related to medication and clinical characteristics in patients older than 50 years with HIV/AIDS newly diagnosis <i>Hoyos Pulgarin, J*;</i> Ramirez Briñez, F; Restrepo, C; Quiceno, A; Alzate, J (Medellín, Colombia)
P010	Cardiovascular risk in elderly patients with HIV. Comparison of Framingham versus D:A:D cardiovascular risk calculators <i>López Hernandez, M* (Mexico City, Mexico)</i>

HIV/Hepatitis Co-infection

P011	Real-world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients co-infected with HCV and HIV-1 <i>Buggisch, P;</i> Moreno, A; Isakov, V; Backus, L; Ain, D; Gonzalez-Garcia, J; Naik, S; Mehta, S; Lee, J; Mertens, M; Llewellyn, J; Natha, M; Kersey, K; Osinusi, A; Slim, J; Zhdanov, K; Berenguer, J; Zeuzem, S; Mendez-Navarro, J* (Mexico City, Mexico)
-------------	--


*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P012 HCV treatment in HIV/HCV co-infection in Brazil, 2016–2017**
*Monzani Vivaldini, S**; Santos, M; Carlos Almeida, E; Alvarenga Pinto, F; Neri Gomes, J; Fernandes, N; Argia Basile Cattapan, E; Jacintho Mendes Correa, M; Moreira Rick, F; Mendes Pereira, G; Tonini, K; Oliveira Bernard, A; Schwartz Benzaken, A (Brasília, Brazil)
- P013 Investigation of the increasing number of hepatitis A cases among men in the biggest city in Latin America in 2017**
*Jorge de Queiroz, M; Alvarenga Pinto, F**; Abrahão Ribeiro, R; Monzani Vivaldini, S; de Almeida Coelho, R; Mendes Pereira, G (Brasília, Brazil)
- P014 Change of evaluation and treatment patterns over a 4-year period of direct-acting antiviral use in HIV/HCV co-infected patients**
*Gonzales Zamora, J; Henry, Z** (Miami, FL, USA)
- P015 HBV mono-infection and HIV/HBV co-infection in Brazil: what are the differences?**
*Alvarenga Pinto, F**; Alves de Souza, F; Santos, M; Monzani Vivaldini, S; Jorge de Queiroz, M; Almeida, E; Mendes Pereira, G (Brasília, Brazil)
- P016 Monitoring hepatitis B and C infections among HIV patients: a proposed model for a cascade of care in viral hepatitis in the Dominican Republic**
*Tapia, L; Peña, P; Matos, Y; Valerio, K; Muñoz, M; Ledesma, J; Jimenez, M; Paulino-Ramirez, R** (Santo Domingo, Dominican Republic)
- P017 Epidemiological characteristics of HIV-positive/hepatitis C virus (HCV) co-infection in Hispanic women**
*Centeno-Alvarado, N**; Wojna, V; Ramos-Perez, E; Barreto, J; Rodriguez-Benitez, R (San Juan, Puerto Rico)
- HIV and Tuberculosis**
- P019 Severe HIV-associated pulmonary tuberculosis, 2006–2016**
*Ricart, J**; Sanchez Cunto, M; Gregori Sabelli, R; Dominguez, C; Saul, P; Chomyn, J; Nano, M; Chacon, N; Chediack, V; Cunto, E (Buenos Aires, Argentina)
- P021 HIV/TB co-infection**
*Ciappina, A**; Bobatto, A; Bechini, F; Boggia, B; Echaide, M; Iriart, J; Lux, A; Urbina, L; Corral, G; Hualde, M; Miglioranza, C; Aquilia, S (Mar del Plata, Argentina)
- HIV and Women, Including MTCT**
- P022 Prevalence of comorbid conditions in a cohort of women living with HIV in Argentina**
*Mauas, R**; Laurido, M; Cabral, L; Cacciari, V; Cassetti, I (Buenos Aires, Argentina)
- P023 Factors associated with virological failure in women with HIV**
*Cabrera, T**; Ramos, U; Nava, C; Almaraz, A; Badial Hernández, F; Langarica, E; Gonzalez, A (Mexico City, Mexico)
- HIV and Vulnerable Populations**
- P024 Overview of healthcare linkage, retention and adherence in young people living with HIV in Brazil**
*Kolling, A**; Camelo Madeira de Moura, M; da Silva Netto, J; Vianna Brizolara, R; Pati Pascom, A; de Barros Perini, F; Schwartz Benzaken, A (Brasília, Brazil)
- P025 Retention in care trends and viral suppression in newly admitted HIV patients in a tertiary centre in Mexico City**
*Barlandas, E; Caro-Vega, Y; Belaunzarán-Zamudio, P; Guerrero-Torres, L; Sierra-Madero, J; Crabtree-Ramírez, B** (Mexico City, Mexico)
- P027 Advanced presentation among HIV/AIDS patients despite universal access to antiretroviral therapy in northern Mexico**
*Gonzalez-Fernandez, E**; Medina-Piñon, I; Ramos-Jimenez, J (Monterrey, Mexico)
- P029 Cardiovascular risk assessment in transgender women in a HIV/STI clinic in a public hospital in Argentina**
*Ballivian, J**; Toibaro, J; Viloría, G; Ivalo, S; Losso, M (Buenos Aires, Argentina)

*Indicates presenting author.







POSTER PRESENTATIONS (continued)

- P030** **First intervention in a gay sauna with rapid tests for HIV infection in the city of Córdoba, Argentina**
*Pedrola, M**; Haag, N; Garcia, J; Munoz, E; Bonilla, C; Alaniz, G; Laurido, M (Venado Tuerto, Argentina)
- P033** **Co-occurring psychosocial problems in transgender women living with HIV enrolled in a clinical trial in Argentina**
*Aristegui, I; Radusky, P; Zalazar, V; Frola, C; Cardozo, N; Gun, A; Fojo, E; Romero, M; Cahn, P; Sued, O** (Buenos Aires, Argentina)
- Models of Care/Scale-Up of Treatment**
- P035** **The continuum of care among very immunosuppressed (less than 100 CD4+ cells) patients in an outpatient clinic in Mexico City: gaps in diagnosis, linkage and retention in care**
*Piñeirúa-Menendez, A**; Del Hoyo, M; Osorno González de León, F; Badial Hernández, F; Niño-Vargas, R (Mexico City, Mexico)
-  **P036** **Prolonged hospital stay and associated factors in patients receiving care in a HIV/AIDS clinic in Mexico City**
*Lara-Medrano, R**; Camiro-Zúñiga, A; Caro-Vega, Y; Crabtree-Ramírez, B; Sierra-Madero, J; Belaunzarán-Zamudio, P (Mexico City, Mexico)
- P037** **Vaccine coverage in adults living with HIV and receiving care in a tertiary care centre in Mexico City, 2005–2016**
*Mendez-Roldan, M**; Olmedo-Reneaum, A; Cano-Torres, J; Camiro-Zuñiga, A; Caro-Vega, Y; Galindo-Fraga, A; Huertas-Jimenez, M; Sierra-Madero, J; Belaunzarán-Zamudio, P (Mexico City, Mexico)
- P038** **HIV clinical monitoring in the southern region of Brazil**
*Mendes Pereira, G; Abrahão Ribeiro, R**; Alvarenga Pinto, F (Brasília, Brazil)
- P039** **Advances in the management model for the provision of HIV genotyping services in Brazil**
*Kohiyama, I**; Alonso, J; Pinho, R; Villares, M; Pires, A (Brasília, Brazil)
- P040** **Reduction of errors during the pre-analytical process for the collection of HIV samples in Mexican centres: a pilot study of a new software strategy implementation**
*Rodriguez-Diaz, R**; Ramos-Hinojosa, A; Orta-Resendiz, A; Angulo-Medina, L; Gomez-Cuellar, J; Sierra-Madero, J; Soto-Ramirez, L (Mexico City, Mexico)
- P041** **The 'no-show' patients in HIV clinical care**
*Sandoval, M**; Kundro, M; Losso, M (Buenos Aires, Argentina)
- P042** **Contribution of SISCEL/SICLOM systems for PLHA monitoring: CTA/environmental dermatology experience/SES/RS in Brazil**
*Machado Alves, D**; Both, N; Torres de Carvalho, F; Alnoch, E; Castoldi, L; Canterle, G (Porto Alegre, Brazil)
- P043** **Provincial differences in the update status of antiretroviral treatments**
*Soullas, G**; Biscay, A; Marovic, M; Mendizabal, M; Maulen, S; Pardo, P (Buenos Aires, Argentina)
- Non-AIDS Morbidities and Mortality, and Ageing**
- P044** **Low frequency of screening for anal carcinoma in a cohort of adult men receiving care for HIV in a third-care, referral centre in Mexico City**
*Gomez-Garcia, L**; Belaunzarán-Zamudio, P; Crabtree-Ramírez, B; Sierra-Madero, J; Caro-Vega, Y (Mexico City, Mexico)
- P045** **Evaluation of cardiovascular risk factors in HIV patients in a public hospital**
*Martini, S**; Falak, A; Aguilar, A; Sued, O; Cahn, P; Perez, H (Buenos Aires, Argentina)
- P046** **In which geographic areas should actions be targeted to reduce HIV/AIDS mortality in Mexico? An analysis of this magnitude, distribution and trends by Jurisdicción Sanitaria, 1990–2015**
*Bravo-García, E; Magis-Rodríguez, C**; Palacios-Martínez, M; Guarneros-Soto, N (Mexico City, Mexico)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

Treatment Strategies and Outcomes

-  **P047 Safety and efficacy of E/C/F/TAF in HIV-infected adults on chronic haemodialysis**
Eron Jr, J; Kalayjian, R; Wurapa, AK; Stephens, J; McDonald, C; Wilkin, A; McKellar, M; Custodio, J; Jiang, S; SenGupta, D; Espinoza, L; Das, M (Foster City, CA, USA)*
-  **P048 Phase 3, randomised, controlled trial of switching to fixed-dose bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: Week 48 results**
Daar, E; DeJesus, E; Ruane, P; Crofoot, G; Creticos, C; Molina, J-M; Koenig, E; Liu, Y; Andreatta, K; Graham, H; Cheng, A; Martin, H; Silva, F; Quirk, E (Foster City, CA, USA)*
-  **P049 Superior efficacy of dolutegravir (DTG) plus two nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus two NRTIs in second-line treatment: interim data from the DAWNING study**
Aboud, M; Kaplan, R; Lombaard, J; Zhang, F; Hidalgo, J; Mamedova, E; Losso, M; Chetchotisakd, P; Sievers, J; Brown, D; Hopking, J; Underwood, M; Nascimento, MC; Gartland, M; Smith, K (Buenos Aires, Argentina)*
-  **P050 Monitoring HIV care in Brazil: a national strategy to reduce the HIV treatment gap**
Vianna Brizolara, R; Kolling, A; da Silva Netto, J; Camelo Madeira de Moura, M; de Barros Perini, F; Schwartz Benzaken, A (Brasília, Brazil)*
- P051 Time of initiation of treatment of people living with HIV**
Uesono, J; Eri Shimizu, H; Díaz Bermudez, X; Merchan-Hamann, E; Moreira Rick, F; Pati Pas, A (Brasília, Brazil)*
- P052 Salvage antiretroviral therapy for the treatment of HIV-1 infection in patients failing a first-line regimen: experience from a national peer advisory committee for physicians in Mexican HIV clinics**
Sánchez-Domínguez, J; Ramírez-Hinojosa, J; Figueroa-Morales, A; Rivera-Villegas, H; Larrea-Schiavon, S; Calva, J; and the CORESAR Study Group (Mexico City, Mexico)*
- P053 Real-life use of raltegravir: experience from Hospital Guillermo Almenara, Lima, Peru**
Malpartida, O; Pérez-Lazo, G; Collins, J; and the Almenara Hospital AIDS Working Group Medicina Interna 1-Infectología (Lima, Peru)*
- P054 The importance of the health team in the search for HIV-infected patients who abandoned treatment**
Carvalho, N (São Paulo, Brazil)*
- ### Viral Hepatitis
-  **P055 High rates of medical and psychiatric comorbidities in HIV/HCV co-infected patients treated with sofosbuvir-containing regimens in registrational clinical trials**
Sulkowski, M; Cooper, C; Molina, J-M; Naggie, S; Osinusi, A; Stamm, L; Massetto, B; McNally, J; Brainard, D; McHutchison, J; Wyles, D; Rockstroh, J; Dieterich, D; Bassetti, E; Campos, A (São Paulo, Brazil)*
-  **P056 SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the Astral-1, Astral-2 and Astral-3 studies**
Agarwal, K; Patel, K; Samuel, D; Bourliere, M; Liu, X; Younes, Z; Liu, L; McNally, J; Osinusi, A; Brainard, D; Subramanian, S; Afdhal, N; Cheinquer, N; Dutra, I (São Paulo, Brazil)*
- P057 Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 HCV-infected patients with severe renal impairment**
Eric, L; Landis, C; Maliakkal, B; Bonacini, M; Ortiz-Lasanta, G; Zhang, J; Mogalian, E; De-Oertel, S; Osinusi, A; Brainard, D; McHutchison, J; Flamm, S; Gordon, S; Gane, E; Chirino, R (Mexico City, Mexico)*
- P058 Genetic diversity of the hepatitis B virus strains in Cuba: absence of West-African genotypes despite the transatlantic slave trade**
Rodriguez Lay, L; Bello Corredor, M; Montalvo Villalba, M; Sariego Frometa, S; Sanchez Wong, M; Valdes Alonso, L; Samada, M; Sausy, A; Hübschen, J; Muller, C (Havana, Cuba)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P059 Analysis of risk factors associated with hepatitis B infection in Paraná correctional institutions in Brazil**
Ferreto, L;* Follador, F; Vieira, A; Bento Casaril, K; Coelho, H; Torres, R; Frois, J; Amaral, G; Yamada, R (Francisco Beltrão, Brazil)
- P060 Anti-HCV seroprevalence and risk factors of HCV infection in penitentiaries in Paraná, Brazil**
Ferreto, L;* Follador, F; Vieira, A; Coelho, H; Yamada, R; Torres, R; Frois, J; Amaral, G (Francisco Beltrão, Brazil)
- P061 Perceptions of hepatitis B and hepatocellular carcinoma among Blacks in South Florida**
Gonzalez-Diaz, J;* Schaefer Solle, N; Martin, P; Kobetz, E; Jones, P (Miami, FL, USA)
- P062 Hepatitis B: detection rates and vaccination coverage in Brazil in 2016**
Alvarenga Pinto, F;* Santos, M; de Almeida Coelho, R; Monzani Vivaldini, S; Mendes Pereira, G; Schwartz Benzaken, A (Brasília, Brazil)
- P063 Android applications for viral hepatitis diagnosis, research and training**
Guadis Salazar, E;* Rodriguez Lay, L; Montalvo Villalba, M; Bello Corredor, M; Lopez Hernandez, D; Marrero Sanchez, B; Sanchez Puente, W (Havana, Cuba)
- P064 Emergence of the transmitted resistance of HIV-1 to antiretroviral drugs in Cuban patients during the period 2009–2016**
Machado Zaldivar, L;* Díaz Torres, H; Blanco de Armas, M; Dubed Echevarria, M; Ruiz, N; Martínez, L; Silva Cabrera, E; López Rizo, L; Romay Franchi, D; Valdés de Calzadilla, N; Nibot, C; Rivero Martínez, C; Joanes Fiol, J; Cancio, I; Rodríguez Acosta, M (San José de las Lajas, Cuba)
- Virology and Immunology**
- P065 Plasma cytokines levels in patients with disseminated Kaposi sarcoma with syphilis and infectious AIDS-defining events**
Volkow, P; Ramon-Luig, L; Chávez-Galán, L; Cornejo-Juárez, P; Vilar-Compte, D; Ocaña-Guzmán, R; Islas-Muñoz, B* (Mexico City, Mexico)
- P066 Co-receptor tropism determined by genotypic assay in HIV-1 non-B subtypes circulating in Cuba. Implications for pathogenesis and maraviroc resistance**
Kourí, V;* Pérez, L; Martínez, Y; Aleman, Y; Díaz, D; Han, R; Pintos, Y; Mendez, M; Soto, Y; Baños, Y; Caturla, Y; Fonseca, C; Pérez, J; Hengge, U (Havana, Cuba)
-

*Indicates presenting author.